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Abstract
Background: Articular cartilage from patients with osteoarthri-
tis is characterized by a decreased concentration and reduced size
of glycosaminoglycans. Degeneration of the cartilage matrix is a
multifactorial process, which is due in part to accelerated
glycosaminoglycan catabolism. Recently, we have demonstrated
that hexosaminidase represents the dominant glycosaminoglycan-
degrading glycosidase released by chondrocytes into the extra-
cellular compartment and is the dominant glycosidase in synovial
fluid from patients with osteoarthritis. Inhibition of hexosamini-
dase activity may represent a novel approach to the prevention of
cartilage matrix glycosaminoglycan degradation and a potentially
new strategy to treat osteoarthritis.
Results : We have synthesized and investigated a series of
iminocyclitols designed as transition-state analog inhibitors of
human hexosaminidase, and demonstrated that the five-membered
iminocyclitol 4 expresses the strongest inhibitory activity with
Ki = 24 nM. Inhibition of hexosaminidase activity in human
cultured articular chondrocytes and human chondrosarcoma cells
with iminocyclitol 4 resulted in accumulation of hyaluronic acid
and sulfated glycosaminoglycans in the cell-associated fraction.
Similarly, incubation of human cartilage tissue with iminocyclitol
4 resulted in an accumulation of glycosaminoglycans in the
pericellular compartment.
Conclusions: Inhibition of hexosaminidase activity represents a
new strategy for preventing or even reversing cartilage degradation
in patients with osteoarthritis. ß 2001 Elsevier Science Ltd. All
rights reserved.
Keywords: Cartilage; Glycosaminoglycan; Hexosaminidase; Iminocycli-
tol ; Inhibitor; Osteoarthritis
1. Introduction
Osteoarthritis is the most common joint disorder. It had
been estimated that in 1990, 12.1% of Americans aged 25
and older (nearly 21 million) had clinical signs and symp-
toms of osteoarthritis [1]. The cost of the illness has risen
over recent decades accounting for up to 1^2.5% of the
gross national product of many industrialized countries
[2,3]. Despite its immense public health impact, the con-
servative treatment of osteoarthritis is limited to a few
classes of medications, such as paracetamol, non-steroidal
anti-in£ammatory drugs, injectable intra-articular cortico-
steroids and hyaluronic acid, which provide primarily
symptomatic relief and have not yet been demonstrated
to interfere with the progression of the disease [4^6].
It is well recognized that articular cartilage from pa-
tients with osteoarthritis and rheumatoid arthritis is char-
acterized by decreased concentrations of proteoglycans
and glycosaminoglycans (GAGs), as well as by a decreased
size of GAG molecules [7]. Loss of articular proteoglycans
in established joint disease could be more signi¢cant than
the collagen loss [8]. In addition to quantitative changes,
a¡ected cartilage also undergoes certain qualitative
changes. Among these changes are a disproportionately
increased ratio of chondroitin 4-sulfate to chondroitin
6-sulfate [9], a decreased ratio of keratan sulfate to chon-
droitin sulfate [9], and decreased sulfation of the terminal
residues in chondroitin and dermatan sulfate chains [10].
GAGs are important sources of hydraulic resistance of
synovial cavities. An acute depletion of hyaluronic acid
and chondroitin sulfate induced by intra-articular injection
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of hyaluronidase resulted in a drastic (5^7-fold) increase in
synovial permeability [11].
Degradation of the cartilage matrix (Fig. 1) is a multi-
factorial process, which is due in part to the action of
metalloproteinases, such as collagenases, stromelysins, ag-
grecanases [12^18], and cysteine proteases such as cathep-
sins [19^21]. Glycosidases represent another important
group of enzymes involved in GAG degradation [22,23].
Recently, we demonstrated that hexosaminidase is the
dominant GAG-degrading glycosidase released by chon-
drocytes into the extracellular compartment, and it is the
dominant glycosidase in synovial £uid of patients with
osteoarthritis [24]. Stimulation of chondrocytes with the
pro-in£ammatory cytokine interleukin-1L results in a se-
lective secretion of hexosaminidase [24].
Hexosaminidase (EC 3.2.1.52) belongs to the group of
lysosomal hydrolases and catalyzes the hydrolysis of ter-
minal, non-reducing N-acetyl-L-D-glucosamine and N-ace-
tyl-L-D-galactosamine residues in glycoproteins, GM2-gan-
gliosides, and GAGs, including chondroitin 4-sulfate,
chondroitin 6-sulfate, hyaluronic acid, keratan sulfate
Fig. 1. Structure of the cartilage matrix extracellular proteoglycan (PG)^hyaluronate complexes and mechanisms of their degradation in arthritic carti-
lage. PG^hyaluronate complexes represent one of the main structural components of the cartilage extracellular matrix. The PG monomers consist of a
protein core with covalently attached side chains of sulfated GAGs (chondroitin sulfate, dermatan sulfate and keratan sulfate). The PG monomers are
non-covalently bound to hyaluronic acid and form PG^hyaluronate complexes. Degradation of the cartilage matrix PGs is a multifactorial process,
which is due in part to the action of glycosidases (including hexosaminidase) and metalloproteinases, such as collagenases, stromelysins, aggrecanases,
and cysteine proteases such as cathepsins.
Fig. 2. The postulated mechanism of hexosaminidase catalysis and a de-
signed transition state analog inhibitor. Hexosaminidase hydrolyzes the
L-glycosidic linkage of L-N-acetylglucosamine or L-N-acetylgalactos-
amine. An oxonium ion transition state is considered to be developed in
the catalytic process. The partial positive charge on the ring oxygen
atom is stabilized by the deprotonated carboxyl group from the enzyme.
Iminocyclitol 4 was designed as a transition state analog inhibitor of the
hexosaminidase.
CHBIOL 110 5-7-01 Cyaan Magenta Geel Zwart
702 Chemistry & Biology 8/7 (2001) 701^711
and dermatan sulfate [22]. Hexosaminidase (Fig. 2) cata-
lyzes the glycosidic hydrolysis of L-N-acetylglucosamine or
L-N-acetylgalactosamine. During the course of catalysis,
an oxonium ion-like transition state is thought to be gen-
erated, which is stabilized by a deprotonated carboxyl
group from the enzyme [25,37]. Human hexosaminidase
has two major isoenzymes, A and B. Hexosaminidase A
(HexA) is a heterodimer composed of K and L subunits,
whereas hexosaminidase B (HexB) is a homodimer com-
posed of L subunits only. Both isoenzymes recognize ter-
minal N-acetylglucosamine and N-acetylgalactosamine,
but only isoenzyme A recognizes 6-sulfated residues of
these sugars [22].
Although hexosaminidase was shown to be produced by
chondrocytes and to possess an enzymatic activity toward
several GAGs, its direct involvement in cartilage matrix
degradation has never been demonstrated. To test the hy-
pothesis that hexosaminidase serves as one of the key en-
zymes participating in cartilage matrix GAG degradation,
we have synthesized iminocyclitol inhibitors of hexosami-
nidase and demonstrated that these agents are capable of
enhancing GAG accumulation in cultured human articular
chondrocytes, cartilage tissue and chondrosarcoma cells.
We have shown that compound 4 is a good inhibitor of
the hexosaminidase in vitro [29], but no further studies
were conducted. Thiazoline inhibitors of other types of
hexosaminidase have also been reported to have good in-
hibition activity in vitro [30]. The iminocyclitols, in which
the ring nitrogen atom carries a positive charge under the
physiological environment [26,27], are believed to be the
transition state analog inhibitors of the enzyme, and many
such structures have been shown to be inhibitors of gly-
cosidases [26^29]. We describe here the application of imi-
nocyclitols as potential chondroprotective agents and sug-
gest a new avenue to the development of drugs to treat
osteoarthritis.
2. Results and discussion
2.1. Synthesis of the iminocyclitol inhibitors
Iminocyclitols (1^8, Scheme 1) were prepared chemo-
enzymatically following the procedure previously reported
from our laboratory [26,28]. The key synthetic step is the
aldol addition reaction of an aldehyde with dihydroxyace-
tone phosphate catalyzed by fructose-1,6-diphosphate al-
dolase.
As mentioned earlier, human hexosaminidase has two
major isoenzymes [22]: HexA and HexB. HexB is a ho-
modimer, which consists of two subunits L, while HexA is
a heterodimer made of subunits K and L. Due to this
di¡erence, HexA can hydrolyze both neutral and nega-
tive-charge substrates, mainly sulfated substrates, while
HexB can only hydrolyze the neutral substrates. There-
fore, selective inhibition of HexA activity may have
more pronounced e¡ects on protection of sulfated GAGs
from enzymatic degradation and spare non-sulfated GAGs
such as hyaluronic acid.
Based on this hypothesis, the 6-hydroxyls of iminocycli-
tols 2 and 4 were sulfated. Following the synthetic route
Scheme 1.
Fig. 3. Synthesis of K-iminocyclitol sulfate 8. Reagents and conditions:
(i) TBDMSCl, TEA, DMF, 0‡C, 88%; (ii) Ac2O, Pyr. 90%; (iii) AcOH/
H2O/THF (5:1:3), 50‡C, 80%; (iv) SO3 WPyr, pyridine, rt, 82%; (v)
NaOMe (cat.), MeOH.
Table 1
Inhibition of 1^10 against hexosaminidases in Ki (nM)
1 2 3 4 5 6 7 8a 9 10a
Ki 240 65 40 24 1.2U103 8.6U102 ^b 5.0U103 1.1U104 1.0U105
1.0U102 c 1.0U104 c
aConcentration at which 50% of the enzyme activity is inhibited.
bNo inhibition at 100 WM.
cInhibition of HexA.
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shown in Fig. 3, the 6-sulfated K-iminocyclitol 8 was pre-
pared from 4.
The hydroxyl groups in L-iminocyclitol 2 seemed much
less reactive than those in K-iminocyclitol 4 (Fig. 4). The
6-hydroxyl did not react with tert-butyldimethylsilyl chlo-
ride even at elevated temperature (130‡C). However, the
primary hydroxyl group of 2 reacted exclusively with tert-
butyldimethylsilyl tri£ate at 0‡C to a¡ord the 6-silyl ether-
protected iminocyclitol 9 in 90% yield. The di¡erent reac-
tivity between 2 and 4 appears to be caused by the di¡er-
ence in orientation of the N-acetyl group.
The remaining two hydroxyls were then protected as
benzyl ethers. The activation of 6-hydroxyl by the benzyl
group was critical for the sulfation reaction. We found
that the diacetyl-protected iminocyclitol 15 did not react
with pyridine sulfur trioxide even under forcing reaction
conditions. Compound 9 was prepared according to the
procedure reported previously by Knapp et al. [30]. Com-
pound 10 was prepared from 9 by reaction with pyridine
sulfur trioxide. Both 9 and 10 were used to see if the
participation of the neighboring C-2 acetamido group
was involved during the degradation of GAGs by the en-
zyme.
2.2. Inhibition activity
All the iminocyclitols were assayed in vitro under the
condition similar to the one described previously [28,29].
The substrate was used in the micromolar range and in-
hibitors in the micro- to nanomolar range. All inhibitors
were found to be potent competitive inhibitors of L-N-
acetylhexoaminidases from human placenta (Table 1). Es-
pecially, the ¢ve-membered iminocyclitol 4 exhibits a Ki of
24 nM. The potent inhibition activity may be attributed to
the protonated iminocyclitol at the physiological pH to
mimic the positive charge of the oxonium ion [26,27].
Since there is less torsion force and more half-chair-like
characteristic in the ¢ve-membered ring [29], the transition
state conformation is mimicked better by the ¢ve-mem-
bered ring than by the six-membered ring system. The
participation of the C-2 acetamido group seems not so
critical here.
2.3. E¡ect of iminocyclitol 4 on extracellular and
intracellular hexosaminidase activity in cultured human
articular chondrocytes
Incubation of human articular chondrocytes with imi-
nocyclitol 4 resulted in a strong, dose-dependent inhibition
of extracellular and intracellular hexosaminidase activities
(Fig. 5). The inhibitor did not a¡ect cell viability measured
by a standard MTT (thiazolyl blue) assay. In addition, the
inhibitor did not a¡ect the extracellular and intracellular
enzymatic activities of K-N-acetylglucosaminidase, L-ga-
lactosidase and hyaluronidase in chondrocyte cultures
(data not shown). Therefore, results of the experiments
demonstrated that compound 4 expresses speci¢c inhibi-
tory activity toward human hexosaminidase in vitro.
2.4. E¡ect of hexosaminidase inhibition on sulfated GAG
and hyaluronic acid accumulation in cultured human
articular chondrocytes and chondrosarcoma cells
Incubation of human chondrosarcoma cells with the
inhibitor 4 resulted in a statistically signi¢cant increase
in the accumulation of cell-associated hyaluronic acid
and sulfated GAGs in the cell-associated fraction, and in
a statistically signi¢cant decrease in secretion of hyaluron-
ic and sulfated GAGs into the supernatant as compared
with untreated cells (Fig. 6). Similar results were obtained
with cultured human articular chondrocytes (Fig. 7). How-
ever, the response of the chondrocytes was more hetero-
geneous than that of chondrosarcoma cells, which most
likely re£ects the heterogeneity in the amplitude of hexos-
aminidase activities in the chondrocytes. Overall, the ex-
Fig. 4. Synthesis of L-iminocyclitol sulfate 7. Reagents and conditions:
(i) TBDMSOTf, TEA, 0‡C, DMF 90%; (ii) BnBr, NaH, 0‡C^rt, 90%;
(iii) TBAF, THF, 4 h, 80%; (iv) SO3 WPyr, pyr, 80%; (v) Pd(OH)2-C,
H2, 75%.
Fig. 5. E¡ect of the iminocyclitol 4 on extracellular (EC) and intracellu-
lar (IC) activities of hexosaminidase in cultured human articular chon-
drocytes. Human articular chondrocytes were incubated with various
concentrations of the iminocyclitol 4 for 24 h at 37‡C. EC hexosamini-
dase activities were measured in culture supernatants. IC hexosamini-
dase activities were measured in cell lysates, which were produced by
solubilization of chondrocytes in equal volumes of Cell Death ELISA1
bu¡er (Boehringer Mannheim, Indianapolis, IN, USA). EC and IC hex-
osaminidase activities in chondrocyte culture without the inhibitor were
used as controls. Vertical axis represents percent hexosaminidase inhibi-
tion, which was calculated as (E460=360 experimental/E460=360 control)
U100%. Horizontal axis represents nM concentrations of the iminocycli-
tol 4 added to cell cultures at time 0 of incubation.
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perimental data have con¢rmed the assumption that hex-
osaminidase participates in degradation of the extracellu-
lar matrix and that the inhibition of hexosaminidase ac-
tivity can decelerate this process.
2.5. E¡ect of hexosaminidase inhibition on morphology of
cultured human cartilage tissue
In order to evaluate the e¡ect of hexosaminidase inhi-
bition on cartilage morphology, human articular cartilage
tissue was incubated with iminocyclitol 4 and subsequently
stained with safranin O to detect sulfated GAGs. Results
of the experiments demonstrated that incubation of carti-
lage tissue with the inhibitor resulted in a remarkable ac-
cumulation of safranin O-positive material in the pericel-
lular cartilage compartment (Fig. 8). Therefore, the
generated histomorphological data also con¢rmed the no-
tion regarding the positive e¡ect of hexosaminidase inhi-
bition on GAG accumulation.
2.6. Sulfated iminocyclitol 8 as a selective inhibitor of
human HexA
The activities of sulfated inhibitors were also investi-
gated, and no inhibition was observed for sulfated L-imi-
nocyclitol 7 at 100 WM range. Incubation of human artic-
ular chondrocytes with iminocyclitol 8 demonstrated a
selective inhibition of HexA in the culture supernatants
(Fig. 9A). In addition, inhibitor 8 showed a better inhibi-
tion activity against human placental HexA (IC50 =
0.1 WM) than the total placental hexosaminidases (IC50 =
5 WM) (Fig. 9B). This result veri¢ed our initial hypothesis.
Although the negative-charge carrying inhibitor is di⁄-
cult to transport through the circulating system [31], pro-
drugs of the sulfated inhibitor may be designed based on
this result. As mentioned earlier, as important components
for the construction of di¡erent tissues and for the display
of secretions of many important functions, GAGs are dis-
tributed with di¡erent ratios of hyaluronic acid (non-sul-
fated) to other sulfated GAGs in di¡erent human tissues
based on their functions. Selective inhibition of the degra-
dation of sulfated GAGs would have fewer side e¡ects on
the metabolism of hyaluronic acid. One example of this
advantage was shown in the inhibition of tumor angio-
genesis and metastasis [32], where sulfated inhibitors
were used to inhibit the heparanase-catalyzed cleavage of
heparan, thus blocking heparan sulfate recognition by
growth factors.
Fig. 6. E¡ect of hexosaminidase inhibition on hyaluronic acid and sulfated GAG accumulation in cultured human chondrosarcoma cell line SW 1353.
Chondrosarcoma cells were incubated with the iminocyclitol 4 (50 WM) for 24 h at 37‡C. Chondrosarcoma cells incubated in the absence of the inhibi-
tor were used as a control. Measurement of hyaluronic acid and metabolic labeling of sulfated GAGs with [35S]sulfate were performed according to the
technique described in Section 4. Bars labeled with letters ‘HI’ represent cells treated with the iminocyclitol 4. Bars labeled with letters ‘ctrl’ represent
untreated chondrosarcoma cells. (A) Concentration of hyaluronic acid (ng/ml) in cell-associated fractions. (B) Concentration of hyaluronic acid (ng/ml)
in supernatants. (C) Metabolic labeling of sulfated GAGs in cell-associated fractions with [35S]sulfate. (D) Metabolic labeling of sulfated GAGs in
supernatants with [35S]sulfate. Vertical axes in C and D represent [35S]sulfate uptake in relative units of radioactivity. Asterisks indicate statistically sig-
ni¢cant di¡erences.
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3. Signi¢cance
The results of our earlier reported experiments demon-
strated that hexosaminidase is one of the dominant glyco-
sidases secreted by human articular chondrocytes in vitro
and it is also one of the dominant glycosidases found in
human synovial £uid [24]. In the present article we de-
scribe data showing that inhibition of hexosaminidase ac-
tivity results in GAG accumulation in cultured human
articular chondrocytes and cartilage.
The idea regarding possible therapeutic bene¢ts from
hexosaminidase inhibition is based on the following obser-
vations. First, Cantz and Kresse [33] established that ¢-
broblasts isolated from patients with Sandho¡ disease ac-
cumulate excessive amounts of GAGs. The impaired
catabolism of GAGs was reversed by addition of hexosa-
minidases [35]. Second, Suzuki et al. [34] demonstrated
that mice de¢cient in both hexosaminidase isoenzymes de-
veloped mucopolysaccharidosis-like pathology. Articular
chondrocytes from hexosaminidase-de¢cient mice were
found to contain increased quantities of GAGs [36]. These
¢ndings con¢rmed the notion that hexosaminidases play a
key role in the degradation of GAGs. The process of
GAG accumulation in hexosaminidase-de¢cient individu-
als is qualitatively opposite to the trend which takes place
in articular cartilage a¡ected by arthritis. Accordingly, in-
hibition of hexosaminidase activity may be considered a
desirable intervention directed toward the prevention of
GAG loss or even restoration of impaired cartilage GAGs.
In the present study we demonstrate that inhibition of
hexosaminidase activity with an iminocyclitol inhibitor re-
sulted in accumulation of GAGs in the cell-associated
fraction and decreased release of GAGs into the culture
supernatant. The data con¢rm two assumptions: (1) hex-
osaminidase participates in the degradation of extracellu-
lar matrix in human cartilage; (2) inhibition of hexos-
aminidase activity with the aid of chemical inhibitors
delays the catabolism of cartilage matrix GAGs.
In summary, the described ¢ndings open a new avenue
in the development of a new class of drugs possessing
chondroprotective activity.
4. Materials and methods
4.1. General methods
The reagents used were purchased from Aldrich, Sigma, or TCI
America. The solvents were reagent grade and used as supplied.
High resolution mass spectra (HRMS) were recorded on a VG
ZAB-ZSE instrument with fast atom ion bombardment (FAB).
1H NMR spectra and 13C NMR were carried out on a Bruker
Fig. 7. E¡ect of hexosaminidase inhibition on hyaluronic acid (A and B) and sulfated GAG accumulation (C and D) in cultured human articular chon-
drocytes. Cultured human articular chondrocytes were incubated with the iminocyclitol 4 (50 WM) for 24 h at 37‡C. Chondrocytes incubated in the ab-
sence of the inhibitor were used as a control. Measurement of hyaluronic acid and metabolic labeling of sulfated GAGs with [35S]sulfate were per-
formed according to the technique described in Section 4. Bars labeled with letters ‘HI’ represent cells treated with the iminocyclitol 4. Bars labeled
with letters ‘ctrl’ represent untreated chondrosarcoma cells. (A) Concentration of hyaluronic acid (ng/ml) in cell-associated fractions. (B) Concentration
of hyaluronic acid (ng/ml) in supernatants. (C) Metabolic labeling of sulfated GAGs in cell-associated fractions with [35S]sulfate. (D) Metabolic labeling
of sulfated GAGs in supernatants with [35S]sulfate. Vertical axes in C and D represent [35S]sulfate uptake in relative units of radioactivity. Asterisks in-
dicate statistically signi¢cant di¡erences.
CHBIOL 110 5-7-01 Cyaan Magenta Geel Zwart
706 Chemistry & Biology 8/7 (2001) 701^711
Fig. 8. E¡ect of hexosaminidase inhibition on histomorphology of cultured human cartilage explants. Human cartilage tissue explants were incubated
with the iminocyclitol 4 (50 WM) for 48 h at 37‡C. Cartilage explants from the same donor incubated with culture medium only were used as controls.
After incubation, the tissue was stained with safranin O. Panels 1 (low magni¢cation) and 2 (high magni¢cation) represent microscopic images of the
control, untreated cartilage explants. Panels 3 (low magni¢cation) and 4 (high magni¢cation) represent microscopic images of the cartilage implants
treated with iminocyclitol 4.
Fig. 9. E¡ect of iminocyclitol 8 on total hexosaminidase and HexA activities in human cultured chondrocytes (A) and in preparation of human placen-
tal hexosaminidase (B). (A) Human articular chondrocytes were cultured with appropriate concentrations of iminocyclitol 8 for 24 h at 38‡C. Total hex-
osaminidase activity was measured in culture supernatants using 4-methylumbelliferyl-N-acetyl-L-D-glucosaminide as a substrate. Activity of HexA was
measured in culture supernatants using 4-methylumbelliferyl-6-sulfo-N-acetyl-L-D-glucosaminide as a substrate. Vertical axis represents relative £uores-
cent units of hexosaminidase activity. Horizontal axis represents concentration of iminocyclitol 8 (WM). (B) Human placental hexosaminidase was used
as a source of the enzyme. Enzymatic reaction was performed in 0.1 M sodium citrate bu¡er pH 4.5, containing appropriate concentrations of iminocy-
clitol 8, for 2 h at 37‡C. Total hexosaminidase activity was measured using 4-methylumbelliferyl-N-acetyl-L-D-glucosaminide as a substrate. Activity of
HexA was measured using 4-methylumbelliferyl-6-sulfo-N-acetyl-L-D-glucosaminide. Vertical axis represents relative £uorescent units of hexosaminidase
activity. Horizontal axis represents concentration of iminocyclitol 8 (WM).
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AMC-400, AMX-500, or AMX-600 instruments. Silica gel 60
(230^240 mesh) from Mallinckrodt was used in chromatogra-
phy.
4.1.1. Thiazoline 6-sulfate 10
To a solution of 55 mg of thiazoline 9 in 4 ml of pyridine was
added 35 mg of SO3WNMe3. The mixture was ¢rst stirred under
0‡C for 2 h, and then stayed at room temperature for 10 h. After
concentration, the residue was puri¢ed by silica gel chromatog-
raphy (methylene chloride/methanol = 4:1) to a¡ord 78 mg (87%)
of 10. 1H NMR (CD3OD) N 2.25 (3H, d, J = 1.9 Hz), 3.54 (1H,
ddd, J = 2.3 Hz and 9.0 Hz), 3.66 (1H, dd, J = 4.5 Hz and 9.0 Hz),
4.07 (1H, dd, J = 4.3 Hz and 4.5 Hz), 4.10 (1H, dd, J = 5.8 Hz and
11.0 Hz), 4.17 (1H, dd, 2.3 Hz and 11.0 Hz), 4.29 (1H, d,
J = 4.5 Hz), 6.32 (1H, d, J = 6.9 Hz); 13C NMR (CD3OD)
N 20.8, 68.9, 71.1, 74.4, 74.7, 80.9, 90.6, 170.9; HRMS
(M+Na) calcd. 322.0031, found 322.0036.
4.1.2. Silyl ether 11
To a 1.2 ml DMF solution containing 70 mg (0.32 mmol)
iminocyclitol 4 was added 84 Wl (0.48 mmol) triethylamine and
then cooled to 0‡C, 72 mg of TBDMSCl (0.46 mmol) was added
and this mixture was stirred for 10 h at room temperature. After
the reaction was completed, the solvent was removed under vac-
uum and the residue was puri¢ed by silica gel chromatography
(CH3Cl/MeOH = 9:1) to a¡ord the silyl ether 11 (93 mg, 88%
yield). 1H NMR (CDCl3) N 0.15 (6H, s), 0.97 (9H, s), 2.00 (3H,
s), 2.51 (3H, s), 2.86^2.90 (1H, td, J = 3.3 Hz, 9.2 Hz), 2.96^2.98
(1H, q, J = 4.1 Hz), 3.24^3.27 (1H, dd, J = 5.5 Hz, 14.0 Hz), 3.56^
3.60 (1H, dd, J = 3.3 Hz, 14.0 Hz), 3.74^3.77 (1H, dd, J = 4.4 Hz,
5.5 Hz), 3.82^3.85 (1H, dd of AB, J = 4.4 Hz, 10.5 Hz), 3.90^3.93
(1H, dd of AB, J = 4.1 Hz, 10.5 Hz), 3.94^3.96 (1H, t, J = 3.8
Hz); 13C NMR(CDCl3) N 35.3, 35.2, 18.5, 22.7, 26.55, 35.2,
39.2, 62.8, 70.2, 71.8, 79.8, 80.8, 173.8; HRMS (M+H) calcd.
333.2204, found 333.2216.
4.1.3. Preparation of iminocyclitol 12
A solution of 7 mg of 9 (0.02 mmol) in 2 ml pyridine was
cooled down to 0‡C and then 0.1 ml Ac2O was added. The mix-
ture was stirred for 5.0 h at room temperature. The solvent was
then removed under vacuum and dried further under high vac-
uum. The residue was puri¢ed by silica gel chromatography
(CH3Cl/MeOH = 9:1) to a¡ord the silyl ether 12 (7.8 mg, 90%
yield). 1H NMR (CDCl3) N 0.08 (3H, s), 0.09 (3H, s), 0.91 (9H,
s), 2.01 (3H, s), 2.08 (3H, s), 2.09 (3H, s), 2.43 (3H, s), 3.04^3.06
(1H, q, J = 3.6 Hz), 3.16^3.20 (1H, m), 3.20^3.23 (1H, dd of AB,
J = 3.0 Hz, 7.2 Hz), 3.57^3.61 (1H, ddd, J = 1.8 Hz, 6.6 Hz,
12.0 Hz), 3.82^3.86 (1H, dd of AB, J = 3.6 Hz, 10.5 Hz), 3.86^
3.89 (1H, dd of AB, J = 4.0 Hz, 10.5 Hz), 4.92^4.94 (1H, dd of
AB, J = 3.1 Hz, 4.9 Hz), 5.13^5.15 (1H, t, J = 2.6 Hz), 6.15 (1H,
br.) ; 13C NMR(CDCl3) N 35.60, 35.57, 18.1, 20.95, 21.04, 23.3,
25.8, 34.0, 37.0, 61.2, 66.6, 68.7, 79.2, 79.3, 170.5, 170.6, 171.0;
HRMS (M+H) calcd. 417.2415, found 417.2420.
4.1.4. Preparation of 13
The silyl ether 10 (7 mg) was dissolved in 0.5 ml of a mixture
solvent (AcOH/H2O/THF = 5:1:3) and stirred for 8 h at 50‡C.
After the reaction was completed, the solvent was removed under
vacuum and the residue was puri¢ed by silica gel chromatogra-
phy (EtOAc/MeOH = 4:1) to yield 13 (4.0 mg, 80%). 1H NMR
(CDCl3) N 2.00 (3H, s), 2.09 (3H, s), 2.11 (3H, s), 2.53 (3H, s),
3.01^3.05 (1H, q, J = 4.0 Hz), 3.18 (1H, m), 3.27^3.31 (1H, dd of
AB, J = 8.0 Hz, 13.5 Hz), 3.55^3.59 (1H, dd, J = 3.7 Hz, 14.0 Hz),
3.73^3.76 (1H, dd of AB, J = 5.1 Hz, 11.7 Hz), 3.77^3.81 (1H, dd
of AB, J = 4.0 Hz, 11.6 Hz), 4.97^5.01 (1H, dd, J = 2.2 Hz,
3.0 Hz), 5.11^5.13 (1H, dd, J = 2.2 Hz, 3.6 Hz); 13C NMR
(CDCl3) N 20.85, 20.89, 22.6, 34.9, 37.4, 60.4, 68.9, 70.2, 80.55,
80.61, 171.95, 172.07, 173.6; HRMS (M+H) calcd. 303.1551,
found 303.1546.
4.1.5. Sulfation of compound 13
Under argon protection, 15 mg of SO3Wpyridine complex and
3 mg (0.01 mmol) of compound 13 were dissolved in 0.5 ml of
pyridine. The mixture was stirred for 6 h at room temperature.
After no starting material was left, the solvent was removed and
the residue was puri¢ed by silica gel chromatography (EtOAc/
MeOH = 2:1) to a¡ord 3.1 mg of 12 (82%). 1H NMR (CD3OD)
N 1.94 (3H, s), 2.04 (3H, s), 2.05 (3H, s), 2.50 (3H, s), 3.11 (1H,
m), 3.25 (2H, m), 3.50^3.54 (1H, dd of AB, J = 4.0 Hz, 17.6 Hz),
4.13^4.16 (1H, dd of AB, J = 3.8 Hz, 14.0 Hz), 4.17^4.21 (1H, dd
of AB, J = 3.0 Hz, 13.6 Hz), 4.89^4.92 (1H, dd, J = 2.6 Hz,
5.2 Hz), 5.04^5.07 (1H, t, J = 3.3 Hz); 13C NMR (CD3OD)
N 21.0(2), 22.8, 35.0, 38.2, 66.7, 68.0, 68.8, 80.5(2), 172.15,
172.23, 173.8; MS(M3H)3 381.
4.1.6. K-Iminocyclitol 6-sulfate 8
2 mg (0.005 mmol) of protected K-iminocyclitol 6-sulfate 14
was dissolved in 2 ml of MeOH and then two drops of a 25%
MeONa solution were added to the solution. The reaction was
completed in 30 min and was quenched by acidic resin (Dowex
50-H). The solvent was then removed and the residue was pu-
ri¢ed by reverse phase column (Lichroprep0 RP-18) to a¡ord
1.8 mg (85%) of the product. 1H NMR (D2O) N 1.94 (3H, s),
2.48 (3H, s), 3.00 (1H, br.), 3.17 (1H, br.), 3.32^3.56 (1H, dd of
AB, J = 6.2 Hz, 14.4 Hz), 3.47^3.51 (1H, dd of AB, J = 4.8 Hz,
14.4 Hz), 3.78^3.81 (1H, t, J = 5.3 Hz), 3.98^4.00 (1H, t,
J = 5.3 Hz), 4.16^4.19 (1H, dd of AB, J = 4.4 Hz, 11.0 Hz),
4.21^4.25 (1H, dd of AB, J = 4.1 Hz, 11.4 Hz); 13C NMR
(D2O) N 22.7, 35.3, 38.4, 66.3, 67.8, 68.4, 77.7, 79.0, 175.5;
HRMS (M3H)3 calcd. 297.0762, found 297.0749.
4.1.7. L-Iminocyclitol 6-silyl ether 15
45 mg (0.2 mmol) of L-iminocyclitol 2 and 60 Wl of triethyl-
amine (0.4 mmol) were dissolved in 2 ml of DMF. The mixture
was cooled down to 0‡C. 71 Wl (0.3 mmol) of TBDMSOTf was
then added dropwise to the reaction system. The reaction was
completed in 1.0 h. After removal of the solvent, the residue
was puri¢ed by silica gel chromatography (CH3Cl/
MeOH = 10:1) to a¡ord 62 mg of 15 (90%). 1H NMR (CDCl3)
N 0.098 (3H, s), 0.103 (3H, s), 0.91 (12H, s), 1.97 (3H, s), 2.39
(3H, s), 2.48^2.50 (1H, m), 2.74^2.77 (1H, m), 3.14^3.16 (1H, dt,
J = 2.9 Hz, 11.0 Hz), 3.64^3.68 (1H, dd, J = 5.0 Hz, 15.0 Hz),
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3.72^3.76 (1H, ddd, J = 2.0 Hz, 7.0 Hz, 14.0 Hz), 3.76^3.80 (2H,
m), 4.14 (1H, dd, J = 4.0 Hz, 6.6 Hz); 13C NMR (CDCl3)
N 35.53, 35.48, 18.1, 21.5, 23.1, 25.8, 25.9, 35.2, 67.6, 77.9,
78.5, 171.4.
4.1.8. Benzylation of 15
70 mg (0.21 mmol) of silyl ether 15 was dissolved in 3 ml of
DMF under argon, the solution was then cooled to 0‡C, 24 mg of
60% NaH (0.56 mmol) was added. The mixture was stirred for
10 min before 101 Wl of BnBr (0.46 mmol) was added. The tem-
perature was then increased to 25‡C. The reaction was completed
after 12 h. The reaction mixture was then poured into 20 ml of
ice-water. The resulting mixture was extracted with EtOAc. The
organic phase was then dried over anhydrous Na2SO4 and con-
centrated. The residue was puri¢ed by silica gel chromatography
(hexane/EtOAc = 1:2) to a¡ord 97 mg of fully protected imino-
cyclitol 16 (90%). 1H NMR (CDCl3) N 0.061 (6H, s), 0.87 (9H, s),
1.68 (3H, s), 2.36 (3H, s), 3.06 (1H, m), 3.16^3.20 (1H, d, J = 14.0
Hz), 3.43^3.48 (1H, ddd, J = 2.2 Hz, 5.9 Hz, 14.0 Hz), 3.58^3.61
(1H, dd, J = 4.8 Hz, 9.2 Hz), 3.71^3.75 (1H, dd, J = 4.4 Hz,
14 Hz), 3.77^3.81 (1H, dd, J = 6.6 Hz, 13.8 Hz), 3.96 (1H, s),
4.53^4.57 (4H, m), 7.27^7.36 (10H, m); HRMS (M+H) calcd.
513.3148, found 513.3165.
4.1.9. L-Iminocyclitol 17
25.8 mg (0.05 mmol) of 16 was dissolved in 3 ml of THF. The
mixture was cooled down to 0‡C. 76 Wl of TBAF solution (1.0 M
in THF) was added dropwise. The mixture was stirred for 4 h at
room temperature until the reaction was completed. The solvent
was removed and the residue was puri¢ed by silica gel chroma-
tography (MeOH/EtOAc = 1:10) to give 16 mg of 17 in 80%
yield. 1H NMR (CDCl3) N 1.73 (3H, s), 2.37 (3H, s), 2.45 (1H,
m), 2.81 (1H, s), 2.92^2.95 (1H, q, J = 5.5 Hz), 3.07^3.10 (1H, d,
J = 14.3 Hz), 3.56^3.60 (1H, dd, J = 9.5 Hz, 5.1 Hz), 3.66^3.70
(1H, ddd, J = 1.8 Hz, 7.3 Hz, 13.9 Hz), 3.75^3.79 (1H, dd,
J = 5.9 Hz, 9.6 Hz), 3.87^3.92 (1H, dd, J = 4.1 Hz, 10.3 Hz),
3.93 (1H, br.), 4.55 (2H, s), 4.57^4.60 (1H, d, J = 11.8 Hz),
4.64^4.66 (1H, d, J = 11.8 Hz), 6.25^6.28 (1H, d, J = 5.2 Hz),
7.28^7.34 (10H, m); HRMS (M+H) calcd.399.2284, found
399.2279.
4.1.10. Sulfation of 15
Compound 17 (14 mg, 0.035 mmol) and SO3Wpyridine (56 mg,
10 eq.) were dissolved in 2 ml of pyridine. The mixture was
stirred for 8 h at room temperature. After the reaction was com-
pleted, the solvent was removed and the residue was puri¢ed by
silica gel chromatography (MeOH/EtOAc = 1:4) to a¡ord 13 mg
of 18 (80%). 1H NMR (CD3OD) N 1.83 (3H, s), 2.52 (3H, s), 2.89
(1H, br.), 3.05 (1H, br.), 3.56^3.59 (1H, dd, J = 3.3Hz, 11.4 Hz),
3.64^3.69 (1H, dd, J = 4.4 Hz, 8.0 Hz), 3.75^3.79 (1H, dd, J = 5.1
Hz, 8.0 Hz), 4.13^4.15 (1H, d, J = 3.3 Hz), 4.47^4.53 (4H, m),
4.65^4.68 (1H, d, J = 1.8 Hz), 4.79^4.80 (1H, d, 9.5 Hz), 7.23^7.34
(10H, m); 13C NMR (CD3OD) 22.7, 41.0, 41.5, 55.3, 69.2, 69.8,
73.0, 74.6, 83.7, 128.85, 128.95, 129.07, 129.6, 129.49, 129.53,
139.4, 139.6, 175.2; MS (M+Na) 501.
4.1.11. L-Iminocyclitol 6-sulfate 7
The benzyl ether-protected iminocyclitol 18 (20 mg, 0.042
nmol) was dissolved in 3 ml of MeOH^H2O (1:1). 30 mg of
Pd(OH)/C was added. The mixture was hydrogenated under 1.0
atm of H2 pressure for 12 h. After the reaction was completed,
the solvent was removed and the residue was puri¢ed by silica gel
chromatography (CH3Cl/MeOH/H2O = 6:4:0.7) to a¡ord 9.3 mg
of 7 (75%). 1H NMR (CD3OD) N 1.99 (3H, s), 2.98 (3H, s), 3.41
(1H, br.), 3.54^3.62 (2H, m), 3.91^3.95 (1H, dd of AB, J = 5.9 Hz,
12.3 Hz), 3.98^4.01 (1H, dd of AB, J = 5.1 Hz, 12.5 Hz), 4.38^
4.40 (1H, d, J = 2.9 Hz), 4.53 (1H, s); MS (M3H)3 297.
4.2. Cell and tissue culture
Human cartilage was obtained from autopsy services, tissue
banks and from the Division of Orthopedic Surgery at Scripps
Clinic. Brie£y, articular cartilage was harvested from the femoral
condyles and the tibial plateaus. All tissue samples were graded
according to the Mankin scale [8]. Chondrocytes were isolated
from the cartilage by collagenase digestion and maintained in
high-density monolayer cultures in Dulbecco’s modi¢ed Eagle’s
medium (DMEM) containing 2% fetal bovine serum. The experi-
ments reported here were performed with ¢rst-passage cells. The
human chondrosarcoma SW 1353 cell line was obtained from
ATCC (catalog no. HTB-94) and maintained in DMEM contain-
ing 2% fetal bovine serum.
4.3. Assay for hexosaminidase activity
4-Methylumbelliferyl-N-acetyl-L-D-glucosamine (TRC, Toron-
to, ON, Canada) at a ¢nal concentration of 0.1 mM in 0.1 M
sodium citrate bu¡er pH 4.5 was used as a substrate for total
hexosaminidase activity. 4-Methylumbelliferyl-6-sulfate-N-acetyl-
L-D-glucosamine (TRC) at a ¢nal concentration of 0.1 mM in
0.1 M sodium citrate bu¡er pH 4.5 was used as a substrate for
HexA activity. Human placental hexosaminidase, cell culture
supernatants or cell lysates were diluted in 0.1 M sodium citrate
bu¡er, pH 4.5, and incubated with the substrate for 2 h at 37‡C.
The reaction was stopped by the addition of 0.5 M sodium gly-
cine bu¡er, pH 10.5. Hexosaminidase activity was measured by
the release of 4-methylumbelliferone, utilizing £uorometry (Ver-
saFluor Fluorometer, Bio-Rad, Hercules, CA, USA) with the
excitation wavelength of 360 nm and the emission wavelength
of 460 nm.
4.4. Hyaluronic acid measurement
The concentration of hyaluronic acid in cell culture superna-
tants and in cell-associated extracts was measured by competitive
ELISA with hyaluronan binding protein [28] as a capture mole-
cule and biotinylated hyaluronic acid as a competitor [29]. Puri-
¢ed hyaluronic acid from human umbilical cord (Sigma) was used
as a standard. Cell-associated hyaluronic acid was extracted with
4 M guanidine chloride, precipitated with 5% potassium acetate
and then redissolved in phosphate-bu¡ered saline.
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4.5. Metabolic labeling with [35S]sulfate
Production and accumulation of sulfated GAGs was measured
using radioactive [35S]sulfate. Brie£y, cells were plated in 96-well
plates and incubated for 24 h in serum-free DMEM containing
[35S]sulfate (20 WCi/ml) with or without hexosaminidase inhibitor.
After incubation, the culture supernatants were harvested and
sulfated GAGs were precipitated with dimethylene blue. Simulta-
neously, cell-associated sulfated GAGs were extracted with 4 M
guanidine chloride and precipitated with 5% potassium acetate in
ethyl alcohol. The measurement of [35S]sulfate incorporation was
performed separately for free and cell-associated fractions of the
sulfated GAGs.
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